Trilaciclib

[2] Trilaciclib may help protect bone marrow cells from damage caused by chemotherapy by inhibiting cyclin-dependent kinase 4/6, a type of enzyme.[2] When damaged, the bone marrow produces fewer of these cells, leading to fatigue, increased risk of infection, and bleeding, among other problems.[1][2] The effectiveness of trilaciclib was evaluated in three randomized, double-blind, placebo-controlled studies in participants with extensive-stage small cell lung cancer.[2] The U.S. Food and Drug Administration (FDA) granted the application for trilaciclib priority review and breakthrough therapy designations.[2] The FDA granted the approval of Cosela to G1 Therapeutics, Inc.[2] This article incorporates public domain material from the United States Department of Health and Human Services
Drugs.comLicense dataDailyMedRoutes ofadministrationIntravenousDrug classCyclin-dependent kinase (CDK) inhibitorATC codeV03AF12Legal status℞-onlyIUPAC nameCAS NumberDrugBankChemSpiderChEMBLFormulaMolar massSMILESmedicationcyclin-dependent kinaseFood and Drug Administrationfirst-in-class medicationindicatedpriority reviewbreakthrough therapypublic domainpublic domain materialClinicalTrials.govDetoxifyingchemotherapyFolic acidmethotrexateFolinic acidUric acidRasburicaseAcroleinnitrogen mustardsanthracyclinesDexrazoxaneAlkylating agentsAmifostineKeratinocyte growth factorPaliferminArginine/lysineGlucarpidase